SLC5A2 and chronic kidney disease: Targeting inflammatory pathways in the context of CKD has had limited success.37, , , –41 It is noteworthy that the beneficial effects of SGLT-2 inhibitors and GLP-1 agonists on renal function may reflect anti-inflammatory responses independent of regulation of blood glucose.42, , , –46